(LLY) Eli Lilly - Overview
Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: NYSE (USA) | Market Cap: 928.882m USD | Total Return: 50% in 12m
Avg Turnover: 3.34B
EPS Trend: 96.5%
Qual. Beats: 1
Rev. Trend: 99.5%
Qual. Beats: 4
Warnings
No concerns identified
Tailwinds
Confidence, Garp
Eli Lilly and Company is a global pharmaceutical firm headquartered in Indianapolis, specializing in the development and manufacturing of treatments for chronic and complex conditions. Its portfolio is heavily weighted toward cardiometabolic health, oncology, immunology, and neuroscience, with a significant focus on incretin-based therapies for diabetes and obesity management.
The company operates within the high-barrier-to-entry biopharmaceutical sector, where growth is driven by rigorous research and development cycles and patent protection. Its business model relies on large-scale clinical trials and strategic collaborations with global partners like Boehringer Ingelheim and Roche to co-develop and commercialize specialized molecular entities.
For a more detailed breakdown of these product pipelines and clinical milestones, you may wish to consult ValueRay. Eli Lilly maintains a diversified revenue stream by targeting high-prevalence diseases such as Alzheimers and rheumatoid arthritis across major international markets including the United States, Europe, and China.
- Mounjaro and Zepbound sales growth drives significant GLP-1 market share expansion
- Manufacturing capacity constraints limit short-term revenue potential for obesity portfolio
- Medicare pricing negotiations and patent expirations pose long-term margin risks
- Kisunla commercialization creates new revenue stream in the Alzheimers market
- Clinical trial success for oral GLP-1 candidates influences future valuation premium
| Net Income: 25.3b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.12 > 0.02 and ΔFCF/TA 13.07 > 1.0 |
| NWC/Revenue: 25.19% < 20% (prev 22.84%; Δ 2.35% < -1%) |
| CFO/TA 0.18 > 3% & CFO 20.5b > Net Income 25.3b |
| Net Debt (38.6b) to EBITDA (33.1b): 1.16 < 3 |
| Current Ratio: 1.50 > 1.5 & < 3 |
| Outstanding Shares: last quarter (895.9m) vs 12m ago -0.52% < -2% |
| Gross Margin: 83.51% > 18% (prev 0.82%; Δ 8.27k% > 0.5%) |
| Asset Turnover: 70.16% > 50% (prev 54.82%; Δ 15.34% > 0%) |
| Interest Coverage Ratio: 35.68 > 6 (EBITDA TTM 33.1b / Interest Expense TTM 883.6m) |
| A: 0.16 (Total Current Assets 54.8b - Total Current Liabilities 36.6b) / Total Assets 117b |
| B: 0.25 (Retained Earnings 29.5b / Total Assets 117b) |
| C: 0.31 (EBIT TTM 31.5b / Avg Total Assets 103b) |
| D: 0.32 (Book Value of Equity 27.3b / Total Liabilities 85.4b) |
| Altman-Z'' = 4.24 = AA |
| DSRI: 1.03 (Receivables 21.2b/14.0b, Revenue 72.2b/49.0b) |
| GMI: 0.98 (GM 83.51% / 81.70%) |
| AQI: 0.91 (AQ_t 0.30 / AQ_t-1 0.33) |
| SGI: 1.47 (Revenue 72.2b / 49.0b) |
| TATA: 0.04 (NI 25.3b - CFO 20.5b) / TA 117b) |
| Beneish M = -2.70 (Cap -4..+1) = A |
As of May 24, 2026, the stock is trading at USD 1041.65 with a total of 2,700,418 shares traded.
Over the past week, the price has changed by +5.98%,
over one month by +15.77%,
over three months by +0.78% and
over the past year by +49.96%.
Eli Lilly has received a consensus analysts rating of 4.24. Therefore, it is recommended to buy LLY.
- StrongBuy: 16
- Buy: 7
- Hold: 4
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 1210 | 16.2% |
P/E Forward = 28.0899
P/S = 12.8567
P/B = 29.1227
P/EG = 1.3658
Revenue TTM = 72.2b USD
EBIT TTM = 31.5b USD
EBITDA TTM = 33.1b USD
Long Term Debt = 39.4b USD (from longTermDebt, last quarter)
Short Term Debt = 4.00b USD (from shortTermDebt, last quarter)
Debt = 43.9b USD (from shortLongTermDebtTotal, last quarter) + Leases 486.7m
Net Debt = 38.6b USD (calculated: Debt 43.9b - CCE 5.28b)
Enterprise Value = 967b USD (929b + Debt 43.9b - CCE 5.28b)
Interest Coverage Ratio = 35.68 (Ebit TTM 31.5b / Interest Expense TTM 883.6m)
EV/FCF = 71.24x (Enterprise Value 967b / FCF TTM 13.6b)
FCF Yield = 1.40% (FCF TTM 13.6b / Enterprise Value 967b)
FCF Margin = 18.80% (FCF TTM 13.6b / Revenue TTM 72.2b)
Net Margin = 34.98% (Net Income TTM 25.3b / Revenue TTM 72.2b)
Gross Margin = 83.51% ((Revenue TTM 72.2b - Cost of Revenue TTM 11.9b) / Revenue TTM)
Gross Margin QoQ = 81.93% (prev 85.05%)
Tobins Q-Ratio = 8.30 (Enterprise Value 967b / Total Assets 117b)
Interest Expense / Debt = 2.01% (Interest Expense 883.6m / Debt 43.9b)
Taxrate = 16.43% (1.45b / 8.85b)
NOPAT = 26.3b (EBIT 31.5b * (1 - 16.43%))
Current Ratio = 1.50 (Total Current Assets 54.8b / Total Current Liabilities 36.6b)
Debt / Equity = 1.41 (Debt 43.9b / totalStockholderEquity, last quarter 31.2b)
Debt / EBITDA = 1.16 (Net Debt 38.6b / EBITDA 33.1b)
Debt / FCF = 2.84 (Net Debt 38.6b / FCF TTM 13.6b)
Total Stockholder Equity = 24.9b (last 4 quarters mean from totalStockholderEquity)
RoA = 24.54% (Net Income 25.3b / Total Assets 117b)
RoE = 101.3% (Net Income TTM 25.3b / Total Stockholder Equity 24.9b)
RoCE = 49.01% (EBIT 31.5b / Capital Employed (Equity 24.9b + L.T.Debt 39.4b))
RoIC = 31.65% (NOPAT 26.3b / Invested Capital 83.2b)
WACC = 8.44% (E(929b)/V(973b) * Re(8.76%) + D(43.9b)/V(973b) * Rd(2.01%) * (1-Tc(0.16)))
Discount Rate = 8.76% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -77.78 | Cagr: -0.40%
[DCF] Terminal Value 75.12% ; FCFF base≈13.6b ; Y1≈13.6b ; Y5≈14.4b
[DCF] Fair Price = 204.8 (EV 221b - Net Debt 38.6b = Equity 183b / Shares 891.7m; r=8.44% [WACC]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: 96.54 | EPS CAGR: 78.63% | SUE: 2.47 | # QB: 1
Revenue Correlation: 99.52 | Revenue CAGR: 37.69% | SUE: 2.35 | # QB: 4
EPS current Quarter (2026-06-30): EPS=8.81 | Chg30d=+9.08% | Revisions=+73% | Analysts=20
EPS next Quarter (2026-09-30): EPS=9.40 | Chg30d=+2.50% | Revisions=+43% | Analysts=19
EPS current Year (2026-12-31): EPS=36.19 | Chg30d=+4.47% | Revisions=+73% | GrowthEPS=+49.5% | GrowthRev=+31.0%
EPS next Year (2027-12-31): EPS=44.44 | Chg30d=+5.48% | Revisions=+70% | GrowthEPS=+22.8% | GrowthRev=+14.8%
[Analyst] Revisions Ratio: +73%